MurmurCast
StoryDiscussion

20VC: $5BN in Revenue, 7 to 7,000 Employees in 9 Months, 206,000 Tests in a Single Day: The Craziest Story in Startups: Curative with Fred Turner

The Twenty Minute VC (20VC): Venture Capital | Startup Funding | The Pitch1h 27m

Fred Turner, CEO of Curative, discusses scaling a COVID testing business to $5B in revenue in 9 months, then pivoting to health insurance where he's now deploying AI agents to transform back-office workflows, replacing legacy SaaS with custom solutions, and achieving 10x productivity gains across contract negotiation, claims processing, and credentialing.

Summary

Fred Turner chronicles his entrepreneurial journey from dairy cow genetics testing (TL Biolabs) through a failed sepsis diagnostics startup (Shield) to founding Curative during the COVID-19 pandemic. He moved from the UK to Silicon Valley at 19 after struggling to raise venture funding in Britain, where investors focused on credentials rather than vision. Through Y Combinator's Summer 2016 batch, he pivoted from animal genetics to human diagnostics, initially launching STD and antibiotic resistance testing before focusing on sepsis detection. When the sepsis Series B fell through in December 2019, the company had three weeks of cash remaining.

With COVID-19's emergence in early 2020, Curative pivoted to testing after the chief scientific officer developed a COVID test in his spare time. Turner acquired a lab license (previously sold for $150K) for $27M using forward revenue from customers, implementing an "orthogonal supply chain" approach by sourcing non-traditional suppliers rather than competing for limited standard consumables. This enabled Curative to scale to 206,000 tests per day by December 2020 with 7,000 employees hired in nine months. Total COVID revenue reached $5B over three years, though the business operated on thin margins during demand valleys, losing money on individual tests outside peak surge periods. The company also administered 2.5M vaccinations, which was unprofitable due to insufficient government reimbursement.

Turner transitioned Curative to health insurance in 2021-2022, recognizing that the payer side—not hospitals or labs—drives behavior in the US healthcare system. With $500M invested from COVID profits, the company now has 1.3B valuation with 650 employees. He has deployed AI agents (particularly one named Gwen powered by Claude) to automate previously manual workflows, replacing nearly 80% of SaaS spending. The contracting agent alone increased contract processing from 100 per week to 100 per day, negotiating terms, redlining Word documents using Python code generation, and signing agreements with Turner's legal signature through DocuSign. Credentialing (verifying doctor licenses) went from 2-3 months and $50 per doctor to 12 hours and $20 using an in-house Claude-based agent. Turner plans to reduce headcount from 650 to around 400 through automation while growing membership, maintaining human care navigators for relationship-driven aspects.

Turner advocates for breaking up healthcare consolidation to restore negotiating balance, notes that AI costs at Curative have increased 6x monthly to millions per month, and believes the models can now handle every back-office task. He argues that SaaS consolidation in enterprises is ending, with companies like Curative canceling $600K Salesforce subscriptions for internal vibe-coded solutions built in two months. He predicts a new role of "agent supervisor" will become critical for managing high-volume exception workflows that agents generate. On broader technology impacts, Turner supports universal basic income to address labor displacement and reframes job elimination positively, noting that back-office roles are inherently unfulfilling work that society will later recognize as obviously automatable.

Turner also co-founded Subcritical with his wife, pursuing subcritical nuclear fission using accelerator-driven systems (based on Carlo Rubbia's energy amplifier concept) as a safer, faster path to nuclear power generation than traditional reactor designs. He met his wife by sharing genome files (VCF) on their first date to verify genetic compatibility before a second date, and they have two young children. Turner predicts Anthropic could reach $10 trillion in valuation, believes AI-driven efficiency gains will expand across industries rather than simply eliminate jobs, and expects developer spending on Anthropic tokens to increase from 3.8% of salary today to 200-500% within three years as engineers transition to supervisory roles and deploy more agents than traditional code.

About this episode

<p dir="ltr">Fred Turner is the Founder and CEO @ Curative, one of the wildest stories in tech. Fred scaled a COVID testing business from $0 to $5BN in revenue and took the team from 7 to 7,000 employees in just 9 months. They did over 206,000 COVID tests in a single day and signed contracts in the 100s of $Ms with several of the largest states. Today, Curative is a unicorn health insurance business taking on the incumbents for one of the largest markets in healthcare. </p> <p dir="ltr">AGENDA:</p> <p dir="ltr">00:00 How Did a Spare-Time COVID Test Become a $5BN Business?</p> <p dir="ltr">07:00 How Do You Go From Testing Cows to STDs, Sepsis and COVID?</p> <p dir="ltr">21:00 When Did Fred Realise COVID Was Massive—and How Did Curative Scale to $5BN?</p> <p dir="ltr">36:00 Why Pivot Into Health Insurance—and What Is Broken About US Healthcare?</p> <p dir="ltr">40:00 How Is AI Rebuilding Curative—and Which Departments Go to Zero?</p> <p dir="ltr">45:00 Is SaaS Dead? Why Is Curative Cutting 80% of Its Software Spend?</p> <p dir="ltr">48:00 Are Legacy Insurers Screwed? What Will Anthropic Be Worth in Three Years?</p> <p dir="ltr">59:00 Will AI Make Companies Smaller? Which Jobs Will Survive?</p> <p dir="ltr">1:10:00 Why Nuclear—and Could Subcritical Become Bigger Than Curative?</p> <p dir="ltr">1:17:00 What Have Marriage and Fatherhood Taught Fred? What Has He Changed His Mind On?</p> <p> </p> <p> </p>

Key Insights

  • Turner argues that the UK venture capital environment in 2015 prioritized credentials over potential, whereas Silicon Valley assessed founder vision and company scale potential, directly enabling his move to the US at age 19 to launch his startup ecosystem journey.
  • Turner claims that existing diagnostic labs like Quest and LabCorp are optimized for efficiency in steady-state operations and cannot 10x capacity quickly because their entire infrastructure and incentive structure assumes gradual, predictable growth rather than pandemic-driven exponential scaling demands.
  • Turner asserts that his 'orthogonal supply chain' strategy—sourcing swabs from electronic testing vendors and filter plates instead of magnetic beads—succeeded where traditional supply chain approaches failed because competitors were fighting over the same constrained resources from two Chinese factories, making incremental competition pointless.
  • Turner found that COVID testing had inverted margin dynamics compared to traditional lab work: the business was highly profitable during peak demand surges but unprofitable during demand valleys because fixed costs (7,000 employees, lab infrastructure) remained constant while test volume collapsed, requiring forward pricing of peak capacity.
  • Turner identifies the payer (health insurer) as the primary lever controlling US healthcare system behavior, explaining that hospitals and providers cannot drive meaningful efficiency because they negotiate with multiple fragmented payers with conflicting demands, whereas a consolidated payer can dictate care patterns.
  • Turner claims that current-generation Claude and other large language models can now execute every back-office workflow at Curative, contradicting his assumption from one year prior that certain complex tasks required human intervention, with the limiting factor being deployment configuration rather than model capability.
  • Turner argues that the credentialing agent reduced processing from 2-3 months to 12 hours by accepting the inherent human skepticism around algorithmic decision-making—getting team buy-in required multiple rounds of internal conviction that delegating contract signing to an AI agent was legally and operationally sound.
  • Turner contends that his Gwen contracting agent succeeded not by replacing the 45-person contracting team but by expanding contract volume from 100 weekly to 100 daily, allowing human contractors to focus on complex hospital system negotiations while the agent handles routine provider contracts through relentless email follow-up (15,000+ customized emails daily).
  • Turner asserts that regulatory burdens in Europe should include a financial penalty for passed regulations to incentivize refinement of existing rules rather than purely additive regulation, arguing that most regulation improves governance signals without measuring downstream real-world effects or efficiency.
  • Turner predicts that developer salary expenditure on Anthropic tokens will increase from 3.8% (current Mark Benioff estimate) to 200-500% within three years as engineers transition from coding to supervising agents, with the cost per agent deployment vastly exceeding individual developer compensation.
  • Turner claims that AI-driven enterprise automation will not simply eliminate jobs but will enable companies to do 10x more work rather than 1x work with 10% fewer people, citing his own experience expanding contract volume 10-fold while maintaining team size, thereby creating expansion scenarios rather than pure labor displacement.
  • Turner argues that the Obamacare provision capping insurance company profit margins at 15% of premiums creates perverse incentives for insurers to increase total healthcare spending rather than improve efficiency, since profit growth requires revenue growth when margin is fixed, directly opposite to societal health cost control goals.

Topics

COVID-19 testing scale and operationsHealth insurance business model and transformationAI agents and workflow automationHealthcare system economics and consolidationLabor displacement and future workforceSaaS replacement with custom AI solutionsNuclear energy and Subcritical startupEntrepreneurial journey from UK to Silicon ValleyAnthropic and token economicsRegulatory environment and compliance automation

Transcript

So our chief scientific officer at Curative had, in his spare time, developed a COVID test. Lockdowns had just started. Everybody was starting to freak out. There was basically nowhere to get a test. What's the single largest contract you signed? In the hundreds of millions of dollars. I think our peak day was 206,000 people tested in a single day. And the company went from about 7,000 to 7,000 employees in those first nine months. The total revenue ended up being about 5 billion over a three-year period. We did 2.5 million vaccinations. That was another service we did. We also lost a ton of money on that. That was a terrible business. We're cutting about 80% of our…

Full transcript available for MurmurCast members

Sign Up to Access
View original source →

More from The Twenty Minute VC (20VC): Venture Capital | Startup Funding | The Pitch

Get AI summaries like this delivered to your inbox daily

Get AI summaries delivered to your inbox

MurmurCast summarizes your YouTube channels, podcasts, and newsletters into one daily email digest.